Phio Pharmaceuticals Stock Soars 9.09% on Cost Control Improvements

On April 10, 2025, Phio Pharmaceuticals' stock surged by 9.09% in pre-market trading, marking a significant uptick in investor interest.

Phio Pharmaceuticals has seen a notable improvement in cost control, with recent reports indicating lower operating losses and growing revenue in the European market. This positive trend is attributed to strategic lab partnerships, which have bolstered the company's financial performance.

Additionally, the company's stock has been gaining traction among investors, with recent trading activity showing a strong upward momentum. This surge in interest is likely driven by the company's efforts to enhance its market position and financial stability.